ArticleCurrent oncology (Toronto, Ont.)2022

Access to Neoadjuvant Pertuzumab for HER2 Positive Breast Cancer in Canada: A Dilemma Increasingly Difficult to Explain.

Daniel Rayson et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.